Inflammation is a significant contributor to cardiovascular disease and its complications; however, whether the myocardial inflammatory response is harmonized after cardiac injury remains to be determined. Some receptors of the innate immune system, including the nucleotide-binding oligomerization domain-like receptors (NLRs), play key roles in the host response after cardiac damage. Nucleotide-binding oligomerization domain containing 1 (NOD1), a member of the NLR family, is expressed in the heart, but its functional role has not been elucidated. We determine whether selective NOD1 activation modulates cardiac function and Ca 2+ signalling.
heart damage contribute to pathological cardiac remodelling. 2 -5 However, it is unclear whether myocardial inflammatory response is harmonized after cardiac injury.
A current view in the field suggests that receptors of the innate immune system are central players in host response after cardiac damage. 6 -8 Toll-like receptors (TLRs) are the best characterized mediators of the innate immune response in the cardiovascular system. In heart, sustained activation of TLRs induces deleterious cardiac remodelling, 9 whereas TLR deletion reduces infarct size in murine models. 10, 11 More recently, other receptors of the innate immune system, such as nucleotide-binding oligomerization domain-like receptors (NLRs), have been implicated in CVDs, including atherosclerosis, dilated cardiomyopathy, and ischaemia/reperfusion injury. 4, 12, 13 Nucleotide-binding oligomerization domain containing 1 (NOD1) is an NLR family member involved in host defense that takes part in the response against certain pathogens by regulating the inflammatory response. 14, 15 NOD1 is a cytosolic receptor that, upon activation, undergoes a conformational change that allows the recruitment and activation of receptor-interacting protein 2 (RIP-2). RIP-2 binds to nuclear factor kB (NF-kB) which then translocates to the nucleus to trigger the expression of pro-inflammatory mediators. 16, 17 NF-kB is a key factor in inflammatory signalling and mediates the majority of the effects following NOD1 activation; indeed, the selectivity and potency of NOD1 agonists are frequently evaluated by their ability to activate NF-kB. 16, 18 NOD1 is involved in many human pathologies including diabetes and cancer; 19 -21 however, its role and relevance in the cardiovascular system are less understood. NOD1 can mediate the inflammatory response in vascular smooth muscle, 22, 23 and recently we demonstrated NOD1 expression in murine heart, fibroblasts, and cardiomyocytes. 24 Although treatment of mice with the selective NOD1 agonist C12-iE-DAP induced an increase in pro-inflammatory and apoptotic responses, 24 its functional role has not been addressed. Cardiac function and Ca 2+ homeostasis are closely coupled in the heart. Cardiac contraction is tightly regulated by changes in intracellular calcium levels. Ca 2+ is a key mediator of electrical activation, ion channel gating, and excitation-contraction coupling (EC coupling). EC coupling is initiated by an action potential that fires a small influx of Ca 2+ via sarcolemmal L-type Ca channels (I CaL ) that trigger a large release of Ca 2+ from the sarcoplasmic reticulum (SR) by ryanodine receptors (RyR 2 ), 25, 26 increasing the intracellular Ca 2+ concentration, [Ca 2+ ] i . This rise in cytosolic Ca 2+ results in the activation of the myofilaments to produce cell contraction. After contraction, Ca 2+ is removed from the cytosol mainly by two mechanisms: (i) Ca 2+ uptake by the SR-ATPase (SERCA) and (ii) Na + /Ca 2+ exchanger (NCX) activation that drives Ca 2+ to the extracellular medium. SERCA activity is modulated by phospholamban (PLB). PLB inhibits the function of SERCA in the unphosphorylated state, but once PLB is phosphorylated, it unbinds from SERCA, which results in Ca 2+ uptake to the SR.
As mentioned earlier, during cardiac EC coupling, Ca 2+ entry through Heart failure is an acquired CVD linked to abnormal diastolic Ca 2+ leak. 30, 31 Furthermore, certain pro-inflammatory cytokines such as cardiotrophin-1, which are involved in some CVDs, may induce proarrhythmogenic effects by increasing the occurrence of Ca 2+ sparks. 32 Using the selective NOD1 agonist, C12-iE-DAP (iE-DAP), we studied the role of NOD1 activation on cardiac function and Ca 2+ homeostasis. 18, 33, 34 Our findings provide the first evidence that NOD1 activation induces a decrease in cardiac contraction in mice, associated with EC coupling impairment, mediated by NF-kB activation. Our data reveal a new pro-inflammatory player in the cardiac system since NOD1 might play an important role in the regulation of cardiac function through modulation of Ca 2+ handling.
Methods

Animal care and cell isolation
The study was conducted following recommendations of the Spanish Animal Care and Use Committee, according to the guidelines for ethical care of experimental animals of the European Union (2010/63/EU). NOD1-deficient mice (NOD1 2/2 ) on a B6 (C57BL6/J) background have been described.
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B6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Wild-type littermates were employed as a control. RT -PCR analysis of NOD1 expression in wild-type and NOD1 2/2 mice confirmed the absence of signal in NOD1-deficent mice (see Supplementary material online, Figure S1 ). Ventricular cardiomyocytes from male mice were isolated using standard enzymatic digestion. 36 Briefly, mice were heparinized (4 U/g IP) and injected with 'buprenorphine' (0.01 mg/kg), and were anaesthetized 30 min later with sodium pentobarbital (50 mg/kg). The hearts were excised and suspended on a Langendorff perfusion apparatus, the ascending aorta was cannulated, and a retrograde perfusion was initiated. The hearts were perfused for 2 -3 min at 36 -378C with a standard calcium-free Tyrode's solution containing 0.2 mM EGTA, and then for 3 -4 min with the same Tyrode's solution containing collagenase type II (Worthington) and 0.1 mM CaCl 2 . The hearts were removed from the Langendorff apparatus, and the ventricles were finely chopped into small pieces and gently stirred for 3 min in standard Tyrode's solution containing 0.1 mM CaCl 2 . Cell suspensions were filtered through a 250 mm nylon mesh, pelleted by centrifugation for 3 min at 20 g, and suspended in Tyrode's solution containing 0.5 mM CaCl 2 . Cells were centrifuged as before and suspended in a storage solution containing 1 mM CaCl 2 . Tyrode's solution contained (in mM): 140 NaCl, 4 KCl, 1.1 MgCl 2 , 10 HEPES, 10 glucose; pH ¼ 7.4 with NaOH.
Treatments
Mice were treated for 3 days with 3.3 mg/kg of C12-iE-DAP: Lauroylg-D-glutamyl-meso-diaminopimelic acid (iE-DAP), vehicle (Veh.), 3.3 mg/ kg of iE-Lys or 3.3 mg/kg of iE-DAP plus 2.5 mg/g of BAY 11 -7082 (BAY) by daily IP injection. The vehicle-injected group was the same for iE-DAP, iE-Lys, and iE-DAP + BAY11-7082 (,0.01% DMSO), and the volume injected was 0.1 mL in all cases. iE-DAP (Invivogen) is a selective NOD1 agonist with significant cell membrane permeability and high potency. 18, 33, 34 iE-Lys (Invivogen) is an inactive analogue of NOD1. BAY11-7082 (Calbiochem) was employed to selectively block the NF-kB pathway.
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Echocardiography recording
M-mode echocardiography was employed to analyse cardiac function. Mice were anaesthetized with 1.5% isoflurane gas, and animals were placed on the Integrated Rail System and Mouse Handling Table (VisualSonics, Toronto, Canada) allowing simultaneous acquisition of temperature data (378C was maintained with the integrated heating pad). The chest of the mouse was carefully shaved, and warm ultrasound transmission gel was employed to permit optimal image quality. Mouse hearts were studied by echocardiography over time, using a high-frequency micro-ultrasound system (Vevo 770, VisualSonics). Parasternal short-axis view images of the heart were recorded using a 30-MHz RMV scan head in a B-mode to allow M-mode recordings by positioning the cursor in the parasternal short-axis view perpendicular to the interventricular septum and posterior wall of the left ventricle. Heart rate, left-ventricle ejection fraction, fractional shortening, left-ventricle end-systolic diameter, left-ventricle end-diastolic diameter, systolic volume, and diastolic volume were determined using the on-site software cardiac package (VisualSonics). (F 0 ) to obtain the fluorescence ratio (F/F 0 ). Ca 2+ sparks were detected using an automated detection system and using a criterion that discriminated the detection of false events while detecting most Ca 2+ sparks. 40 
Intracellular calcium imaging
I CaL recording
Recording of L-type Ca 2+ current (I CaL ) was performed at room temperature (22 + 28C) using the whole-cell configuration of the patch clamp technique. The patch pipette resistance was 1.0-1.2 MV. I CaL was recorded using an Axopatch 200B (Axon Instruments). Current traces were digitized using Digidata 1322A and analysed using pClamp8 software (Axon Instruments). From a holding potential of 250 mV, voltage pulses (duration 300 ms) between 240 to +60 mV (with 10 mV steps) were applied at a frequency of 0.2 Hz. Ca 2+ currents were normalized with cell capacitance to obtain current density. Membrane capacitance (C m ) was elicited by applying +10 mV voltage steps from 260 mV, and C m was calculated according to the equation:
where t c is the time constant of the membrane capacitance, I 0 the maximum capacitance current value, E m the amplitude of the voltage step, and I the amplitude of the steady-state current. The extracellular solution for I CaL recordings contained (in mM): 140 NaCl, 1.1 MgCl 2 , 5.4 CsCl, 10 glucose, 5 HEPES, 1.8 CaCl 2 ; pH adjusted to 7.4 with NaOH. The intracellular recording pipette solution contained (in mM): 100 CsCl, 20 TEACl, 5 EGTA, 10 HEPES, 5 Na 2 ATP, 0.4 Na 2 GTP, 5 Na 2 creatine phosphate, 0.06 CaCl 2 ; pH adjusted to 7.4 with CsOH.
Western blot analysis
Cardiomyocytes were homogenized in a buffer containing (in mM): 50 Tris, 320 sucrose, 1 DTT, and protease/phosphatase inhibition cocktail (SigmaAldrich). Homogenates were centrifuged at 13 000 g for 15 min at 48C, and cleared supernatants were used for immunoblotting. Proteins were separated on SDS -PAGE gels and then transferred to PVDF membranes. Membranes were blocked with 5% BSA and incubated overnight with the following primary antibodies: SERCA2a, phospho-PLB (Ser16), phospho-PLB (Thr17) and PLB, phospho-RyR 2 (Ser2815), phospho-RyR 2 (Ser2808) (Badrilla Ltd.), RyR 2 (Affinity Bioreagents), NCX (Swant antibodies), and GAPDH (Ambion). Membranes were then incubated with peroxidaselinked secondary antibodies (1:5.000) in 2% BSA for 60 min at room temperature. Immunoreactive bands were detected using the Amersham TM ECL TM Protein Detection System.
Statistics
Data are presented as mean + SEM. Statistical analysis on the number of isolated cells/samples was carried out using a nested ANOVA, and post hoc comparisons were performed by Bonferroni's test. All statistical analyses were made using the SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). Significance was assumed when P , 0.05.
Results
NOD1 activation induces cardiac dysfunction and impairment in EC coupling
C12-iE-DAP (iE-DAP) is a widely used selective agonist of NOD1. 18, 33, 34 We evaluated whether iE-DAP administration in mice was detrimental to cardiac function. Compared with vehicle-treated mice, ejection fraction, fractional shortening, and systolic volume were all decreased in mice treated for 3 days with iE-DAP ( Table 1) . However, heart rate, leftventricle end-diastolic and end-systolic diameter, and also heart weight: body weight ratio, were unaffected by iE-DAP treatment ( Table 1) .
Since cardiac function and Ca 2+ homeostasis are closely coupled in the heart, we investigated whether the reduced cardiac function induced by iE-DAP was associated with an impairment of EC coupling. I CaL is a key player in cardiac EC coupling, chiefly through its ability to trigger [Ca 2+ ] i transients. 26 Using the patch clamp technique in the whole-cell configuration, we recorded I CaL in myocytes isolated from vehicle or iE-DAP-treated mice. Average I CaL density from 0 to +40 mV was significantly reduced (P , 0.05) in iE-DAP-treated mice NOD1 and calcium handling compared with vehicle-treated counterparts ( Figure 1A ). Moreover, iE-DAP significantly reduced the maximal I CaL peak density obtained at +10 mV vs. vehicle ( -5.3 + 0.5 pA/pF, n ¼ 9 in iE-DAP vs. 28.2 + 0.7 pA/pF, n ¼ 14 in vehicle P , 0.05). Notably, cardiomyocytes isolated from mice treated with the inactive analogue of iE-DAP, iE-Lys, exhibited similar values of I CaL density to the vehicle group ( Figure 1A) . The diminution on I CaL induced by iE-DAP treatment can be related to changes in the I CaL inactivation curve. Indeed, cardiomyocytes obtained from iE-DAP-treated mice exhibited a shift in the voltage dependence of I CaL inactivation towards more negative values; the voltage of half-maximal inactivation was (V 50 ) 219.8 + 1.8 mV in vehicle and 226.5 + 1.9 mV in iE-DAP group (P , 0.05; see Supplementary material online, Figure S2A ). Importantly, no changes in the mRNA expression of the molecular correlate of I CaL , Cav 1.2, were detected between groups (see Supplementary material online, Figure S2B ).
Subsequently, [Ca 2+ ] i transients electrically evoked by field stimulation at 2 Hz were recorded by confocal microscopy. An example of a line-scan image taken from a cardiomyocyte isolated from vehicle-, iE-DAP-, or iE-Lys-treated mice is shown in Figure 1B (Figure 2A ) and SERCA expression ( Figure 2C) were decreased in the iE-DAP group compared with vehicle-treated mice.
In contrast, phosphorylation of PLB at threonine 17 was unchanged between groups ( Figure 2B ). Since SERCA function (k SERCA) can be assessed systematically from the decay rates of the systolic and caffeine-evoked Ca transients, 41 we calculated k SERCA by subtracting the rate constant of decay of the caffeine-evoked transient from that of the systolic Ca 2+ transients.
We found that k SERCA was 100 + 0.1% (n ¼ 5) in vehicle and 77.7 + 0.1% (n ¼ 6) in iE-DAP group (P , 0.001), supporting the idea that iE-DAP administration induces a decrease in the SERCA function.
On other hand, the decay time of caffeine-evoked [Ca 2+ ] i transients were increased in the iE-DAP-treated group ( Figure 1C, right panel) , suggesting an impairment of the Na + /Ca 2+ exchange (NCX) function. Thus, we investigated whether the expression of NCX was affected by the NOD1 agonist. As shown in Figure 2D , NCX protein levels were significantly decreased in the iE-DAP group vs. Figure 3B ), as well as a significant reduction in cell contraction ( Figure 3C ), compared with vehicle-treated cells. Figure 4A . A significantly higher frequency of Ca 2+ sparks was observed in cardiomyocytes taken from iE-DAP-treated mice compared with cardiomyocytes obtained from vehicle controls ( Figure 4B) . A comparison of the properties of the Ca 2+ sparks showed that the amplitude was significantly lower in cardiomyocytes taken from iE-DAP-treated mice compared with those obtained from vehicletreated mice ( Figure 4C ). This reduction in amplitude in cells isolated from iE-DAP-treated mice was due largely to a significant increase (39%, see Supplementary material online, Table S1 ) in the population of events with peaks around 1.3 (F/F 0 ), with a concomitant reduction of Ca 2+ sparks with higher (above 1.5 F/F 0 ) amplitudes, as shown by histogram distribution (see Supplementary material online, Figure S3A ). In contrast, the average duration and width of Ca 2+ sparks were unchanged between groups ( Figure 4C) . Similarly, histogram distributions of Ca 2+ spark durations and widths were comparable in cells isolated from iE-DAP-and vehicle-treated mice (see Supplementary material online, Figure S3B and C ). Calculation of the overall spark-mediated Ca 2+ leak gave an increase of 4.7-fold after iE-DAP treatment (see Supplementary material online, Figure S4 ). showed that the intracellular [Ca 2+ ] i measured using Fura-2 (R340/ R380) was significantly higher in cardiomyocytes isolated from iE-DAP-treated mice compared with equivalent vehicle-treated mice (see Supplementary material online, Figure S6 ). As described above, Ca 2+ spark recordings reflect the in situ activity of RyR 2 . 27 Since Ca 2+ spark frequency data pointed to augmented RyR 2 activity following iE-DAP treatment, we measured phosphorylation of RyR 2 at ser2808 (site for mainly PKA activation) and ser2815 (site for CaMKII activation). Results from immunoblotting showed that ser2808 phosphorylation of RyR 2 was significantly increased after iE-DAP treatment ( Figure 4D ), whereas ser2815 phosphorylation of RyR 2 was unchanged ( Figure 4E ). 
iE-DAP exerts a selective effect on EC coupling
To corroborate the selectivity of iE-DAP for Ca 2+ handling modulation, we used cardiomyocytes isolated from NOD1-deficient mice (NOD1 2/2 ). We found that iE-DAP administration resulted in similar Figure S7) . Thus, the lack of an effect of iE-DAP in NOD1 2/2 mice to induce changes in EC coupling supports the selectivity of iE-DAP on Ca 2+ signalling.
NF-kB mediates iE-DAP-induced changes in EC coupling and cardiac function
Since we previously showed that iE-DAP treatment induces specific NF-kB activation in cardiac tissue and isolated cardiomyocytes, 24 we assessed whether NF-kB activation could mediate the effect of iE-DAP on Ca 2+ dynamics. To do this, we employed the selective NF-kB inhibitor, BAY11-7082 (BAY). 37 -39 In comparison with mice treated with iE-DAP alone, isolated cardiomyocytes from mice treated for 3 days with iE-DAP plus BAY had similar I CaL values to vehicletreated mice ( Figure 6A) . Moreover, co-treatment with BAY abrogated the iE-DAP-induced effects on amplitude and decay time of [Ca 2+ ] i transients, as well as cell contraction parameters ( Figure 6B) . Additionally, immunoblotting of cardiomyocytes demonstrated that co-treatment with BAY prevented both the iE-DAP-induced decrease in SERCA protein expression and PLB phosphorylation at ser16 ( Figure 6C ). Finally, co-treatment of BAY plus iE-DAP prevented the depressed cardiac function induced by iE-DAP administration alone ( Figure 7C and Table 1 ). Taken together, these studies support the concept that the NF-kB pathway underlies the iE-DAP-induced effect on both cardiac dysfunction and impairment in cardiomyocyte Ca 2+ handling.
Discussion
Our study provides the first direct evidence that selective activation of the innate immune receptor NOD1 results in cardiac dysfunction related to EC coupling impairment mediated through NF-kB signalling.
The innate immune system acts as a 'first warning response' to pathogens, infection, or organ injury. The best described mediators of the innate immune system are TLRs and NLRs. Both receptor families contain pattern recognition motifs that distinguish between self and non-self, by recognizing pathogen molecular motifs or endogenous host material derived from cellular injury/death. Cardiac damage activates some of these receptors to induce a protective response for tissue repair. 43 -45 However, sustained activation of the innate immune system frequently results in maladaptive responses and leads to an increase in pro-inflammatory cytokines levels, which promote pathological cardiac remodelling. 45 Accordingly, up-regulation of TLR activity induces cardiac damage while mutations or targeted disruption of TLRs reduce infarct size, preventing cardiac dysfunction induced by ischaemia/reperfusion or myocardial infarction, and boost the stability atherosclerotic lesions. 11,46 -49 In addition to TLRs, NLRs are also cytosolic receptors of the innate immune system that play an important role in regulating the inflammatory response. 22 Recently, several studies have attributed roles for these mediators in CVDs; in particular, the NLR NLRP3 has been NOD1 and calcium handling demonstrated to mediate pathological processes including atherosclerosis and dilated cardiomyopathy. 4, 12, 13 NOD1 is a member of the NLR family that is expressed ubiquitously. NOD1 regulates the inflammatory response in vascular smooth muscle, 22 and long-term treatment of mice with selective NOD1 agonists promotes vascular complications including coronary arteritis and valvulitis. 50 While NOD1 is expressed in murine cardiomyocytes, 24 its functional role in the heart has not yet been established. In the present study, we found that NOD1 activation promotes a significant decrease in cardiac function, a feature shared by the majority of CVDs including heart failure, diabetic cardiomyopathy, and ischaemiareperfusion injury. Moreover, cardiac dysfunction induced by administration of the NOD1 agonist iE-DAP was associated with an impairment in EC coupling in isolated murine cardiomyocytes; specifically, cardiomyocytes isolated from iE-DAP-treated mice displayed lower [Ca 2+ ] i transients amplitude compared with vehicle-treated counterparts. This effect could be due to modulation of (i) Ca 2+ current, (ii) RyR 2 activity, (iii) and/or SR-Ca 2+ load. Figure 1B) ; and also that iE-DAP administration induces a decrease in the SERCA function of around 20% (K SERCA) compared with veh. group. So, iE-DAP treatment gets SERCA working at least at 80% to maintain SR Ca 2+ content at a level sufficient that is enough to sustain spark-mediated Ca 2+ leak (not below of 400 mM, which could stop the release of Ca 2+ in the form of sparks). Another key aspect is that although iE-DAP induces an increase in Ca 2+ spark number, the mean amplitude of Ca 2+ sparks was significantly lower in the iE-DAP group compared with the vehicle ones ( Figure 4C ), reducing the amount of Ca 2+ released as Ca 2+ sparks.
It was important to validate the NOD1 agonist iE-DAP. Although the selectivity of iE-DAP has been addressed by several studies in different organs and cells, we verified that iE-DAP exerts a selective effect on Ca 2+ cycling in isolated myocytes. Accordingly, mice treated with the inactive analogue of iE-DAP, iE-Lys, and NOD1-deficient mice treated with iE-DAP, failed to modify the cardiac EC coupling parameters. 
NOD1 and calcium handling
This selectivity strengthens the findings that NOD1 participates in the regulation of Ca 2+ handling.
Mechanistically, we show that the detrimental effect on Ca 2+ handling and cardiac function induced by iE-DAP is mediated by the NF-kB pathway. NF-kB is a central player in the inflammatory response and mediates many of the effects derived from NOD1 activation. The precise role of NF-kB in heart remains controversial since both adaptive and maladaptive actions have been described. Thus, early NF-kB activation following acute cardiac damage may support adaptive mechanisms to prevent pathological remodelling. In contrast, sustained NF-kB activation would be maladaptive by preserving the inflammatory response. 61, 62 In this context, the selective blockade of NF-kB may provide protection against ischaemia reperfusion damage, attenuating infarct size, reducing inflammation and cell death events, and improving cardiac function. 63 -65 NF-kB is involved in multiple signalling pathways related to Ca prevented the Ca 2+ handling effects induced by administration of iE-DAP (Figures 6 and 7) . Supporting these data, a recent report by Zhang et al. 65 has shown that NF-kB loss of function protects against cardiac damage by maintaining Ca 2+ cycling. In this study, deletion of the NF-kB subunit p65 was associated with augmented SR-Ca 2+ release and elevated PLB phosphorylation at ser16. These results suggest that NF-kB can modulate the Ca 2+ SR uptake through PKA activation. Consistent with this, our results also show that NF-kB mediates the iE-DAP-induced effects on Ca 2+ homeostasis, and blockade of the NF-kB pathway prevents also the PKA phosphorylation effects induced by the NOD1 agonist on PLB and RyR 2 .
In conclusion, our results describe a new role for NOD1 outside of the immune setting, highlighting the importance of the pro-inflammatory response and its consequences on cardiac function ( Figure 7D) . Importantly, the effects of NOD1 activation in the heart share many of the features detected in relevant CVDs, such as heart failure. In this context, in addition to apoptotic and fibrotic events, the NOD1 agonist induces cardiac dysfunction by Ca 2+ cycling impairment; all of which are detected in human and experimental models of heart failure. Notably, CVDs linked to RyR 2 gain of function show excessive channel activity that is associated with cardiac arrhythmias and contractile dysfunction, in addition to pathological cardiac remodelling. Our findings point to NOD1 as an important regulator of both systolic and diastolic Ca 2+ release, and may provide a basis for the development of novel strategies for therapeutic intervention of Ca 2+ handling impairment in specific CVD, such as dilated cardiomyopathy or ischaemia/reperfusion injury, where NLR activation has been described.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
